Skip to Content
Søk Menu

Combination treatment of AML with spleen tyrosine kinase

In this MEDtalk Philipp Sergeev, MSc, Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Finland, presents the results of treatment with entospletinib and lanraplenib. Lanraplenib is a next generation oral SYK inhibitor with potency and selectivity comparable to entospletinib.
Philipp Sergeev

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Gunnar Juliusson

Cytarabine Dose Intensification Improves Survival in Older Patients with AML

/ Gunnar Juliusson
AML Play the Video 08:21

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ BestPractice Nordic
AMLEHA24
Nikolaj Nitschke

Functional Characterization for Germline Variants in Patients with MDS and AML

/ Nikolaj Juul Nitschke
AMLEHA24 Play the Video 03:17

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

/ Sigrid S. Skånland
AMLCLL
Jad Othman

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

/ Jad Othman
AMLASH23 Play the Video 03:32

ASH 2023: Oral Decitabine-Cedazuridine Tablet Shows Promise for AML Treatment in Phase III Study

/ BestPractice Nordic
AMLASH23
Sergio Giralt

In the Era of Personalized Treatment and Targeted Therapies

/ Sergio Giralt
AMLASH23 Play the Video 2:46

Promising Results from EHA23: Gilteritinib as Posttransplant Maintenance Therapy for FLT3-ITD AML Patients

/ BestPractice Nordic
AMLEHA23

FLT3 Inhibitor Gilteritinib Shows Potential in Post-Transplant Maintenance for AML

/ Mark Levis
AMLEHA23 Play the Video 05:06
Back to top